Headache Sciences Incorporated
Clinical artificial-intelligence company developing an EEG-based diagnostic and monitoring service for migraine. The organization combines EEG signal processing, machine learning classifiers and source-localization visualization to identify interictal migraine biomarkers, has peer-reviewed publications and an awarded US patent for its diagnostic approach, and is running IRB-approved clinical studies to validate its algorithms and prototypes.
Industries
N/A
Nr. of Employees
small (1-50)
Headache Sciences Incorporated
Patents
Products
EEG-based migraine diagnostic prototype (SaMD)
Prototype diagnostic system using machine-learning analysis of EEG to identify interictal migraine predisposition and subtype (migraine with aura, migraine without aura).
EEG-based migraine diagnostic prototype (SaMD)
Prototype diagnostic system using machine-learning analysis of EEG to identify interictal migraine predisposition and subtype (migraine with aura, migraine without aura).
Services
Recruitment and enrollment of participants, collection of standardized multi-lead EEG recordings, and data-generation for validation of diagnostic algorithms.
Provision of EEG recording according to defined multi-lead protocol (32 leads) to generate data compatible with machine-learning diagnostic algorithms.
Recruitment and enrollment of participants, collection of standardized multi-lead EEG recordings, and data-generation for validation of diagnostic algorithms.
Provision of EEG recording according to defined multi-lead protocol (32 leads) to generate data compatible with machine-learning diagnostic algorithms.
Expertise Areas
- EEG signal processing
- Biomarker discovery and validation
- Machine learning for clinical diagnostics
- SaMD (software-as-a-medical-device) development
Key Technologies
- Electroencephalography (EEG)
- Machine learning classification (non-linear SVM)
- Biosignal signal processing
- Source localization for EEG
News & Updates
Clinical trials for biomarker validation commenced (September 3, 2022).
Received FDA correspondence (July 13, 2022) providing a roadmap for applying for breakthrough status for chronic migraine pending additional research.
Unconditional IRB ethics approval obtained to validate existing biomarkers and discover additional biomarkers (June 9, 2022).
Peer-reviewed proof-of-concept publication describing machine-learning methods applied to EEG for migraine with aura classification.
US patent awarded for an expert-system approach to diagnosing migraine using machine learning applied to EEG.
Pilot study achieving ~92.9% classification accuracy for migraine with aura (interictal) versus controls; additional preliminary 3-class results reported.
Clinical trials for biomarker validation commenced (September 3, 2022).
Received FDA correspondence (July 13, 2022) providing a roadmap for applying for breakthrough status for chronic migraine pending additional research.
Unconditional IRB ethics approval obtained to validate existing biomarkers and discover additional biomarkers (June 9, 2022).
Peer-reviewed proof-of-concept publication describing machine-learning methods applied to EEG for migraine with aura classification.
US patent awarded for an expert-system approach to diagnosing migraine using machine learning applied to EEG.
Pilot study achieving ~92.9% classification accuracy for migraine with aura (interictal) versus controls; additional preliminary 3-class results reported.